Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-BETTER: XB2001 + ONIVYDE + 5-FU/LV in Advanced Pancreatic Cancer
NCT04825288Phase 2Completed
- Sponsor
- XBiotech Inc.
- Start
- May 2021
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of XB2001 in pancreatic cancer (PC), sponsored by XBiotech Inc.. Started May 2021; status: completed.
02
Drugs
XB2001
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04825288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04825288.